Tissue-Link ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  20.7% 14.9% 20.1% 10.6% 22.3%  
Credit score (0-100)  5 13 5 22 4  
Credit rating  B BB B BB B  
Credit limit (kDKK)  -0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  -214 367 -231 16.6 -399  
EBITDA  -214 367 -231 16.6 -399  
EBIT  -214 367 -231 16.6 -399  
Pre-tax profit (PTP)  -215.6 365.7 -235.2 5.8 -408.3  
Net earnings  -189.3 326.5 -183.9 5.8 -319.1  
Pre-tax profit without non-rec. items  -216 366 -235 5.8 -408  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  88.8 415 231 237 -81.9  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  104 490 247 254 1,397  

Net Debt  -54.7 -413 -130 -85.7 -1,303  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -214 367 -231 16.6 -399  
Gross profit growth  -525.3% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  104 490 247 254 1,397  
Balance sheet change%  -66.1% 372.4% -49.6% 3.0% 448.9%  
Added value  -214.1 366.8 -230.8 16.6 -398.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 1.0 -1.0 1.0 -1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -104.5% 123.4% -62.6% 6.8% -45.8%  
ROI %  -115.8% 145.5% -71.4% 7.2% -334.3%  
ROE %  -103.2% 129.5% -56.9% 2.5% -39.1%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  85.6% 84.7% 93.7% 93.2% -5.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  25.5% -112.5% 56.4% -518.1% 326.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  113.8% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  6.9 6.5 15.8 14.8 1.4  
Current Ratio  6.9 6.5 15.8 14.8 1.4  
Cash and cash equivalent  54.7 412.8 130.2 85.7 1,302.9  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  88.8 415.3 231.4 237.2 418.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0